This is a working overview of thymosin beta-4, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-28. Anything still debated is marked as such rather than presented as settled.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
=== PD-1 === Pembrolizumab (Keytruda, formerly MK-3475 and lambrolizumab) was developed by Merck and first approved by the Food and Drug Administration in 2014 for the treatment of melanoma. It was later approved for metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. In 2017, it became the first immunotherapy drug approved for use based on the genetic mutations of the tumor rather than the site of the tumor. It was shown that patients with higher non-synonymous mutation burden in their tumors respond better to the treatment. Both their objective response rate and progression-free survival was shown to be higher than in patients with low non-synonymous mutation burden. Nivolumab (Opdivo) was developed by Bristol-Myers Squibb and first approved by the FDA in 2014 for the treatment of melanoma. It was later approved for squamous cell lung cancer, renal cell carcinoma, and Hodgkin's lymphoma. Cemiplimab (Libtayo) was developed by Regeneron Pharmaceuticals and first approved by the FDA in 2018 for the treatment of cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. Dostarlimab (Jemperli) – was developed by GlaxoSmithKline and was first approved for the treatment of mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer by the FDA in April of 2021. On August 17, 2021, the FDA granted accelerated approval for the treatment of mismatch repair deficient (dMMR) recurrent or advanced solid tumors.
Both Agincourt Collegiate Institute and R. H. King Academy claim to be the oldest secondary schools in the district. Agincourt Collegiate Institute (the former Agincourt Continuation School) opened in 1915. It became a high school in 1954. R. H. King Academy opened in 1922 as the Scarborough High School being the first high school in the Scarborough area at that time, and became a collegiate in 1930. Four public school boards operate primary and secondary schools in the district: Conseil scolaire catholique MonAvenir (CSCM), Conseil scolaire Viamonde (CSV), the Toronto Catholic District School Board (TCDSB), and the Toronto District School Board (TDSB). CSV and TDSB operate as secular public school boards, the former operating French first language institutiona, whereas the latter operates English first language institutions. The other two school boards, CSCM and TCDSB, operate as public separate school boards, the former operating French first-language separate schools, the latter operating English first-language separate schools. As of 2008, there are 28 secondary schools in Scarborough. In addition to primary and secondary schools, two post-secondary institutions are located in Scarborough. The University of Toronto maintains a Scarborough campus, established in 1964, which has an enrolment of more than 15,000 students as of 2024. Centennial College was opened in 1966. It was the first vocational college to open in Ontario. Starting from one campus in Warden Woods, it grew to three campuses across Scarborough (and two others located in East York and North York).
The territory of Hanover had earlier been a principality within the Holy Roman Empire before being elevated into an electorate in 1708, when Hanover was formed by the union of the dynastic divisions of the Duchy of Brunswick-Lüneburg, excepting the Principality of Brunswick-Wolfenbüttel. After his accession in 1714, George Louis of the House of Hanover ascended the throne of Great Britain as George I, and Hanover was joined in a personal union with Great Britain. In 1803, Hanover was conquered by the French and Prussian armies in the Napoleonic Wars. The Treaties of Tilsit in 1807 joined it to territories from Prussia and created the Kingdom of Westphalia, ruled by Napoleon's youngest brother, Jérôme Bonaparte. French control lasted until October 1813, when the territory was overrun by Russian Cossacks. The Battle of Leipzig, shortly thereafter, spelled the definitive end of the Napoleonic client states, and the electorate was restored to the House of Hanover. The terms of the Congress of Vienna in 1814 not only restored Hanover but also elevated it to an independent kingdom with its Prince-Elector, George III of the United Kingdom, as King of Hanover. The new kingdom was also greatly expanded and became the fourth-largest state in the German Confederation (behind Prussia, Austria and Bavaria) and the second-largest in northern Germany. George III never visited the kingdom during his 60-year reign.
=== Maternal === Fetal AFP levels can be monitored in the urine of pregnant women. Since AFP is quickly cleared from the mother's serum via her kidneys, maternal urine AFP correlates with fetal serum levels, although the maternal urine level is much lower than the fetal serum level. AFP levels rise until about week 32. Maternal serum alpha-fetoprotein (MSAFP) screening is performed at 16 to 18 weeks of gestation. If MSAFP levels indicate an anomaly, amniocentesis may be offered to the patient.
Sources: en.wikipedia.org
is the number of amino acid residues, R1 is the first residue of the protein P, R2 is the second residue, and so forth. The problem with this approach was that in some sequence-similarity-search-based tools, the query protein often lacked significant homology (or sequence similarity) with any other known protein in the database. To resolve this problem, discrete models for representing protein samples were proposed. The simplest discrete model is using the amino acid composition (AAC) to represent protein samples. Under the AAC model, the protein P of Eq.1 can also be expressed by
== History == The detection of nitrates and nitrites for GSR has been around since the early 1900s. The first recorded use of paraffin wax as a lifting medium was done by Dr. Iturrioz in 1914 and was popularized in 1933 by Teodoro Gonzalez of the Mexico City Police Laboratory. The aptly named paraffin test is also referred to as the diphenylamine test, dermal nitrate test and the Gonzalez test. This test consisted of coating a suspect's hands with paraffin wax, allowing it to solidify and peeling it away before adding a diphenylamine/sulfuric acid reagent. The presence of dark blue spots is said to indicate a positive result. This is no longer used in casework due to the high number of false positives caused by the commonality of nitrates and nitrites in a variety of mundane products such as fertilisers. In 1971 John Boehm presented some micrographs of gunshot residue particles found during the examination of bullet entrance holes using a scanning electron microscope. If the scanning electron microscope is equipped with an energy-dispersive X-ray spectroscopy detector, the chemical elements present in such particles, mainly lead, antimony and barium, can be identified. In 1979 Wolten et al. proposed a classification of gunshot residue based on composition, morphology, and size. Four compositions were considered characteristic:
gene silencing Any mechanism of gene regulation which drastically reduces or completely prevents the expression of a particular gene. Gene silencing may occur naturally during either transcription or translation. Laboratory techniques often exploit natural silencing mechanisms to achieve gene knockdown.
== Governance and regulatory issues == Xenobiology might challenge the regulatory framework, as currently laws and directives deal with genetically modified organisms and do not directly mention chemically or genomically modified organisms. Taking into account that real xenobiology organisms are not expected in the next few years, policy makers do have some time at hand to prepare themselves for an upcoming governance challenge. Since 2012, the following groups have picked up the topic as a developing governance issue: policy advisers in the US, four National Biosafety Boards in Europe, the European Molecular Biology Organisation, and the European Commission's Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) in three opinions (Definition, risk assessment methodologies and safety aspects, and risks to the environment and biodiversity related to synthetic biology and research priorities in the field of synthetic biology.).
Whether or not green biotechnology products such as this are ultimately more environmentally friendly is a topic of considerable debate. It is commonly considered as the next phase of green revolution, which can be seen as a platform to eradicate world hunger by using technologies which enable the production of more fertile and resistant, towards biotic and abiotic stress, plants and ensures application of environmentally friendly fertilizers and the use of biopesticides, it is mainly focused on the development of agriculture. On the other hand, some of the uses of green biotechnology involve microorganisms to clean and reduce waste. Red biotechnology is the use of biotechnology in the medical and pharmaceutical industries, and health preservation. This branch involves the production of vaccines and antibiotics, regenerative therapies, creation of artificial organs and new diagnostics of diseases. As well as the development of hormones, stem cells, antibodies, siRNA and diagnostic tests. White biotechnology, also known as industrial biotechnology, is biotechnology applied to industrial processes. An example is the designing of an organism to produce a useful chemical. Another example is the using of enzymes as industrial catalysts to either produce valuable chemicals or destroy hazardous/polluting chemicals. White biotechnology tends to consume less in resources than traditional processes used to produce industrial goods.
Sources: en.wikipedia.org
Supporters of continued collecting also point to the greater scientific utility and legacy of museum specimens compared to blood samples or photographs, and argue that collecting for research offers the only source of avian mortality with a positive outcome for birds in terms of the biological knowledge gained. Although taking small blood samples from wild birds is often viewed as a harmless alternative to collecting, it reduces survival by as much as 33% and does not provide the benefits of a voucher specimen. Scientists have pointed out that bird populations represent renewable resources, and that scientific collecting represents only a tiny and non-additive proportion of annual bird mortality. However, examples exist of species whose extinction was directly contributed to by museum collecting (e.g. Guadalupe caracara, ivory-billed woodpecker). The last bird of the extinct Black Mamo from Molokai was shot for collecting.
A process in which a person is given important facts about a medical procedure or treatment, a clinical trial, or genetic testing before deciding whether or not to participate. It also includes informing the patient when there is new information that may affect his or her decision to continue. Informed consent includes information about the possible risks, benefits, and limits of the procedure, treatment, trial, or genetic testing. (NCI) The process of learning the key facts about a clinical trial before deciding whether or not to participate. It is also a continuing process throughout the study to provide information for participants. To help someone decide whether or not to participate, the doctors and nurses involved in the trial explain the details of the study. (NLM) A process by which a subject voluntarily confirms his or her willingness to participate in a particular trial, after having been informed of all aspects of the trial that are relevant to the subject's decision to participate. Informed consent is documented by means of a written, signed, and dated informed consent form. (ICH E6) Informed consent document
=== Social issues === Paetongtarn is socially liberal on many issues. She supports LGBT rights and attended the Bangkok Pride Parade in 2023 along with the MFP's Pita Limjaroenrat. Additionally, she supports rewriting the constitution and scrapping military conscription. However, she opposes amending Thailand's lèse-majesté laws. Like her party, Paetongtarn supports stricter drug control and tough-on-crime measures. Although Paetongtarn and the PTP pledged not to form a government with military-linked parties such as United Thai Nation and Palang Pracharath, the PTP-led government consisted of both parties which led to widespread criticism.
== Clinical significance == Mutations in this gene have been associated with tardive dyskinesia (TD), an increased risk of hematotoxicity after exposure to benzene, and susceptibility to various forms of cancer. Altered expression of this protein has been seen in many tumors and is also associated with Alzheimer's disease (AD).
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.